Pfizer (NYSE: PFE) CEO receives 25 phantom stock units as compensation

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Chairman and CEO Albert Bourla received a routine compensation grant of 25 Phantom Stock Units under the company’s Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after his separation from service.

Following this award, Bourla holds a total of 772,979 phantom stock units. These units are a cash-settled, non-trading derivative tied to Pfizer’s common stock value and can be moved into an alternative investment account at his discretion, rather than being bought or sold on the open market.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BOURLA ALBERT

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units SSP	25	$24.08	$602.00

Holdings After Transaction: Phantom Stock Units SSP — 772,979 shares (Direct, null)

Footnotes (1)

Each unit represents one phantom share of common stock. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Key Figures

Phantom units granted: 25 Phantom Stock Units Grant reference price: $24.08 per unit Total phantom units held: 772,979 units +2 more

5 metrics

Phantom units granted 25 Phantom Stock Units Grant on 2026-06-30 under deferred compensation plan

Grant reference price $24.08 per unit Price per phantom stock unit for this award

Total phantom units held 772,979 units Total phantom stock units following the transaction

Underlying common stock equivalent 25 shares Each unit represents one phantom share of common stock

Conversion price $0.00 Phantom units are cash-settled, non-exercisable derivatives

Key Terms

Phantom Stock Units SSP, Nonfunded Deferred Compensation and Supplemental Savings Plan, phantom share of common stock, settled in cash

4 terms

Phantom Stock Units SSP financial

"Security title is listed as "Phantom Stock Units SSP" in the transaction."

Nonfunded Deferred Compensation and Supplemental Savings Plan financial

"Units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan."

settled in cash financial

"These units ... are settled in cash following the reporting person's separation from service."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 03:50 PM Accepted by SEC EDGAR 07/01/2026 - 03:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOURLA ALBERT

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

10001-2192

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock Units SSP	⁽¹⁾	06/30/2026		A		25		⁽²⁾	⁽²⁾	Common Stock	25	$24.08	772,979	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

	/s/ Shanice A. Reid, by power of atty., for Albert Bourla	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pfizer (PFE) CEO Albert Bourla report in this Form 4 filing?

Albert Bourla reported receiving 25 Phantom Stock Units as compensation. These units are granted under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and are linked to the value of Pfizer common stock but settled only in cash after his separation from service.

How many phantom stock units does Pfizer CEO Albert Bourla now hold?

After this grant, Albert Bourla holds a total of 772,979 phantom stock units. This figure reflects his cumulative phantom stock-based compensation, which tracks Pfizer’s common stock value but is not itself tradable equity and will be paid out in cash in the future.

What are Phantom Stock Units in the context of Pfizer (PFE)?

Pfizer’s Phantom Stock Units each represent one phantom share of common stock. They mirror the value of Pfizer shares but are part of a deferred compensation program, settled in cash after the executive leaves the company rather than through delivery of actual shares in the market.

Was this Pfizer Form 4 transaction a stock purchase or sale by Albert Bourla?

No, this transaction was not an open-market stock purchase or sale. It reflects a grant of 25 Phantom Stock Units as compensation, classified as a derivative award, with no shares bought or sold on the market and settlement occurring only in future cash form.

When will Albert Bourla’s Pfizer phantom stock units be settled?

The phantom stock units are scheduled to be settled in cash after Albert Bourla’s separation from service. Until then, they remain bookkeeping entries under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and may be reallocated into an alternative investment account at his choice.